Blog
RSS FeedPosted by Michael Wonder on 24 Sep 2023
NICE recommends Lilly's mirikizumab (Omvoh) for the treatment of eligible adults with moderately to severely active ulcerative colitis
22 September 2023 - Eli Lilly announced today that NICE has recommended mirikizumab for the treatment of adults with moderately ...
Posted by Michael Wonder on 22 Sep 2023
PMPRB report shows increased plan costs, promising pharmaceutical innovation: expert
20 September 2023 - A recent report by the Patented Medicine Prices Review Board shows increased growth for private drug ...
Posted by Michael Wonder on 21 Sep 2023
Updates to the Health Technology Assessment Policy and Methods Review Reference Committee – 22 September 2023
21 September 2023 - The agenda for this week's HTA Review Reference Committee meeting is now available. ...
Posted by Michael Wonder on 20 Sep 2023
Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency
20 September 2023 - NICE has published evidence-based recommendations on the use of pembrolizumab (Keytruda) for the adults with previously ...
Posted by Michael Wonder on 20 Sep 2023
Access to COVID-19 anti-viral treatments widened for more people at risk
20 September 2023 - PHARMAC is widening access to COVID-19 anti-virals to people who are vulnerable to severe infection from ...
Posted by Michael Wonder on 20 Sep 2023
International HTA collaboration expands
20 September 2023 - The international collaboration between six health technology assessment bodies from across the UK, Australia and Canada ...
Posted by Michael Wonder on 19 Sep 2023
How IQWiG assesses – version 7.0 of the method paper comes into force
19 September 2023 - Fundamental revision of the cost benefit assessment and addition of the concept of application-accompanying data collection. ...
Posted by Michael Wonder on 18 Sep 2023
COVID-19 vaccine contract summary
18 September 2023 - The Ministry of Health has released a summary of the New Zealand Government’s procurement process for ...
Posted by Michael Wonder on 18 Sep 2023
New form of fast-acting insulin added to the PBS
18 September 2023 - The Albanese Government is listing a new form of fast-acting insulin on the PBS from 1 ...
Posted by Michael Wonder on 15 Sep 2023
Another uninformative update from the Health Technology Assessment Policy and Methods Review Reference Committee
15 September 2023 - The agenda for the HTA Review Reference Committee meeting of 14 September 2023 is now available. ...
Posted by Michael Wonder on 14 Sep 2023
First treatment for acute migraine to be recommended by NICE set to benefit thousands
14 September 2023 - The first treatment to be recommended by NICE for treating acute migraine will soon be available on ...
Posted by Michael Wonder on 14 Sep 2023
Here we go again - version 4
14 September 2023 - The Department has today published version 4 of the agenda for the November 2023 PBAC meeting. ...
Posted by Michael Wonder on 13 Sep 2023
Paladin Labs announced favourable CADTH recommendation for Xcopri (cenobamate tablets)
12 September 2023 - Paladin Labs announced today that CADTH has recommended that Xcopri (cenobamate) be publicly reimbursed as adjunctive therapy ...
Posted by Michael Wonder on 13 Sep 2023
Treatment options for people with glioma, a type of brain cancer
13 September 2023 - BMS, the supplier of lomustine, a treatment used for a type of brain cancer called glioma, is ...
Posted by Michael Wonder on 12 Sep 2023
NICE issues two recommendations for UCB's inflammatory disease drug
11 September 2023 - NICE has issued final draft guidance recommending UCB's Bimzelx (bimekizumab), with the inflammatory disease drug now ...